Novartis IMS Company Profile

Publication Date	March 2009
Publisher	IMS Health
Product Type	Report
Pages	225
ISBN Number	not applicable
Product Code	IMS00022

Buy this product or for assistance call +44 20 7060 7474

PDF £510.00$848 | €571

FAX Order above formats by FAX

Summary

IMS Health's Company Profiles give you the authoritative insight into a company at a strategic and local level.

Each individual IMS Company Profile analyzes the critical components that make up a pharmaceutical company, providing you with a clear assessment of the relative strengths and weaknesses of a company's business strategy.

Critical analyses provided by an in-house expert team
90+ full in-depth company profiles covering all major pharmaceutical companies worldwide
Generic, Biotechnology and Drug Delivery companies
Includes IMS Health sales data on products and therapies
In depth product and R&D reviews, including clinical trial, lifecycle management, competition and analysts forecasts
Mergers and acquisitions; licensing agreements
Forecasts and comments from leading financial analysts
Companies' conferences, annual reports, press releases
Comments from stockbrokers/analysts reports used throughout the profile and especially within the Strategy, Financial and Product sections.

Content

Corporate Structure
Strategy statement
Highlights a company?s strengths / weaknesses and its potential for future growth. The strategy analysis gives you an insight into the following:
- M&A
- Regional strategies
- Therapeutic focus
- R&D strategy
- Licensing activities
- Commentary on future prospects, including brokers? overviews
- Interview with a key person (where available), including quotes and opinions
- Forecasting table (top 30 companies only), showing events with major potential impact
Financial Review
Company sales performance as well as analyst?s comments and forecasts.
Company Sales Performance:
- Financial review
- Latest results
- Sales by geographical region & leading country
- Sales by country and subsidiary
- Analysis comments
Product Portfolio
Company Profiles reviews up to 40 products per company, whilst annual reports from the top 10 pharmaceutical companies cover up to a maximum of 10 drugs.
The section shows:
- Summary table of products facing patent expiry.
- Breakdown by relevant therapy area, within which, each product is discussed under the following headings: general, licensing, patents, clinical data, lifecycle management, competition and analysts? forecasts/comments.
R&D Pipelines
Comprehensive details of the projects that the company has in its R&D pipeline including:
- Research pipeline summary table.
- Introduction to the R&D activities of the company.
- Breakdown by relevant therapy area, within which, each project is detailed (up to 2 A4 pages), including information on clinical status and analysts? forecasts.
- Quotes from senior personnel gleaned from conferences may also be included in this section when available.
Key figures
- Sales by business segment.
- Sales by geographical region.
Analyst figures
IMS sales data
- Pharmaceutical sales by geographical region and leading countries.
- Top 5 third level therapeutic classes.
- Leading international products
- Pharmaceutical sales analysis by age
Employee data
Licensing/Co-Marketing Agreements
Displayed in a tabular format to enable you to have ?at a glance? review of the licensing activities of the company.
Three sections are available to review licensing activities:
- Marketed products
- R&D pipeline products
- General research collaborations, including combinatorial chemistry, proprietary technologies etc.
Major Events
Summary of the major events that have affected the company. This includes recent and historical events.
Two sections
- Mergers and Acquisitions
- Other major events
Events are organised in chronological order.
Subsidiaries listing
Mini-profile of each subsidiary that the company has worldwide showing address, major contacts and principal products.
Other IMS Company Profiles